Symbolbild · KI-generiert
Novavax, Inc.
Stock factsheet
Company data from public sources (TMX Money, Canadian Securities Exchange, Nasdaq screener, Wikidata); every ISIN is verified against its check digit. Where „—“ appears, no verified value exists — we do not publish unverified identifiers. Market capitalisation is an order of magnitude as of the date shown, not a real-time figure. The size class follows the thresholds in common use (micro < $300m, small < $2bn, mid < $10bn) and is meant as an indication, not a definition.
Company profile
Novavax is a US biotechnology company that develops and commercialises vaccines based on protein nanoparticle technology. The company became widely known through its COVID-19 vaccine Nuvaxovid. It is also working on influenza and combination vaccines.
Short profile generated automatically and checked for plausibility. A full editorial profile follows once we cover the company.
Share price
Price data from TradingView, possibly delayed. Not investment advice.
Comparable companies
Companies in the Biotech & Pharma sector of a similar size.
| Company | Ticker | Exchange | Market cap |
|---|---|---|---|
| Novavax, Inc. | NVAX | NASDAQ | 1,20 Mrd. USD |
| Inhibrx Biosciences, Inc. | INBX | NASDAQ | 1,20 Mrd. USD |
| Freenome, Inc. Common stock | FRNM | NASDAQ | 1,20 Mrd. USD |
| STAAR Surgical Company | STAA | NASDAQ | 1,21 Mrd. USD |
| Absci Corporation | ABSI | NASDAQ | 1,21 Mrd. USD |
| Aktis Oncology, Inc. Common stock | AKTS | NASDAQ | 1,22 Mrd. USD |
| Ardelyx, Inc. | ARDX | NASDAQ | 1,22 Mrd. USD |
Investor Relations
We link only to primary sources from the company itself and from the regulators. Fields we have not recorded stay empty until a reliable source is available.
Information and education only — not investment advice, not a recommendation and not a financial analysis within the meaning of §85 WpHG or Art. 20 MAR. Investments in small and micro caps are highly speculative; total loss is possible. All information without warranty.